Physician profile
Thomas Pitoscia
NPI 1770586307
$11,068.50
in general payments reported to CMS, 2019-2025
57 companies · $1,273 in 2025
The $1,273 reported for 2025 was more than what 88% of Adolescent Medicine (Internal Medicine) providers received nationally (typical 2025 total: $165).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,313 · 2020: $1,716 · 2021: $1,852 · 2022: $1,911 · 2023: $1,624 · 2024: $1,379 · 2025: $1,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,275.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,990.34 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,537.30 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $896.06 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $666.55 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $627.19 | 2019-2023 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $520.56 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $514.12 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $419.25 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $370.81 | 2019-2024 | Mounjaro, Jardiance |
| Amarin Pharma, INC. | $339.95 | 2019-2023 | |
| Pfizer INC. | $236.16 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $216.15 | 2019-2023 | Livalo, Seglentis |
| Ibsa Pharma INC. | $207.08 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $206.68 | 2019-2024 | |
| Exact Sciences Corporation | $202.62 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Pitoscia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.